ScaleReady’s Post

CAR-T cell therapy holds immense promise, but traditional transfection methods can compromise cell health. In this application with Avectas , the health of Triple Knock-Out (KO) transfected T-cells was evaluated by measuring cell expansion and viability in a Gas Permeable Rapid Expansion G-Rex platform using different cell culture media and cytokine supplement. The app note explores: • Solupore®'s performance with Triple Knock-Out (KO) T cells • Consistent expansion across different culture media • High viability throughout the process Download the app note now to unlock the full potential of CAR-T therapies with G-Rex: https://lnkd.in/eN3-psyp #CARTTherapy #CellManufacturing #Solupore #NonViral #Transfection #Efficiency #Viability

Our team recently dove into an analysis of the opportunities, challenges, and specific commercialization considerations for cell therapy in Autoimmune disease.

Cell therapies, specifically CAR-T cell therapies, have seen increasing commercial success within oncology and are delivering transformative outcomes for patients. Autoimmune disease is poised as the next frontier for these powerful technologies. Our team recently developed a white paper highlighting the current situation, rationale, competitive trends, and outlook for cell therapy in autoimmune diseases, as well as considerations and requirements for successful commercialization. Dig into our findings below or on our website at: https://lnkd.in/eRHmkEDD To connect with the team to discuss these findings or anything cell therapy related, please reach out to Partner Michael Iacoviello, PhD via LinkedIn or directly at miacoviello@lifesciconsulting.com Robert Humkey, PhD Michael Iacoviello, PhD, Alexander Advani, PhD, Dan Sajewski #celltherapy #strategyconsulting #autoimmune

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

Carcinomas account for ~90% of cancers. This is why the recent FDA approval of TIL therapy is changing the field of cell therapy. In this podcast, Jason Bock talks with Daniel Levine about this achievement and what is on the horizon with the brilliant next generation TILs in development and in the clinic. #biotech #celltherapy #TILtherapy #endcancer https://lnkd.in/et-A5hUe

How can we design more effective T cell therapies? 🤔 Join us for an insightful discussion with Eric de Sousa, Ph.D. candidate and bioinformatician in the Markus Maeurer Lab at the Champalimaud Foundation, for a webinar on June 5th with iRepertoire, Inc.. Eric will present recent data showing differences in TCR repertoires of TILs and their functional phenotypes from various tumor zones. He will also discuss how the TME may impart a particular epigenetic imprint on TILs, information that can be leveraged to develop better cell therapies. Sign up for the webinar today: https://hubs.li/Q02xZXBn0 #TILs #Tcells #TumorMicroenvironment #EpthelialCancer #TcellReceptor #CellTherapy #TCRSequencing #TumorCells #CancerResearch

🌟 Exploring the Promise of Cell Therapy 🌟 Cell therapy is revolutionizing medicine by transferring specific cell types to treat or prevent diseases like cancer and blood disorders. Techniques like autologous (using one's own cells) and allogeneic (using donor cells) therapy showcase the science's versatility. While offering hope for previously untreatable conditions, challenges include immune compatibility and risks like immune responses or organ toxicity. Learn more about this life-changing innovation via ASGCT’s Cell Therapy Basics. #CellTherapy #HealthcareInnovation #StemCell#Exosome

Here's a webinar that may be of interest for the immunotherapy and CRISPR minded of you out there. From the #UniversityofWisconsin-Madison, Dr. Krishna Saha will present on using NK cells as a cell therapy. This is a viral-free method and will expand on how to evade the NK-inhibitory ligands found in many tumors. Check it out! https://lnkd.in/gemm-aFF

Hello Folks! My first post is out! Exciting advancements in CAR T cell therapy, particularly allogeneic approaches, hold promise for revolutionizing cancer treatment. Allogeneic therapies, such as those developed by Allogene Therapeutics, utilize T cells from healthy donors, offering a scalable and accessible alternative to traditional autologous therapies. Innovations in suicide gene systems and gene editing technologies enhance safety and efficacy. Regulatory considerations, including patient enrollment challenges, risk-benefit assessments, and manufacturing requirements, are crucial for ensuring patient safety and treatment efficacy. By addressing these considerations and advancing innovative products, allogeneic CAR T cell therapies have the potential to transform the landscape of cancer treatment. #CARTtherapy #Oncology #RegulatoryConsiderations #Healthcare #Innovation Please do give this a read!

See how high-throughput sequencing of the TCR repertoire contributes to molecularly defining TIL cell therapy products and gauging population diversity to provide fuller insight into the tumor microenvironment and therapy efficacy. Watch the full webinar from iRepertoire now: https://hubs.li/Q02J0JGQ0 #TILs #Tcells #TumorMicroenvironment #EpthelialCancer #TcellReceptor #CellTherapy #TCRSequencing #TumorCells #CancerResearch